Member Info for PM2022

The ironic part is the more rubbish you talk Porky the people learn the facts and the more undervalued we look. Bit daft because you will get corrected and the more people learn the more they will see an opportunity to invest at these bargain prices.

Don't lose anymore sleep Porky9.

@ Porky

That was for buy and build which shareholders voted down so stop lying and manipulating.

@Ratcliffwriter

Thank you for highlighting the previous 125:1 consolidation. Great point

NOTE CAREFULLY CLINICAL TRIALS ARE EXPENSIVE. VALIRX DOES NOT DO CLINICAL TRIALS ANYMORE. SPEND PER YEAR IS JUST OVER 2 MILLION ONLY. ONLY 100 MILLION SHARES.

ALSO NOTE NEW BOD AND CEO NOT THE OLD BOD TEAM.

I HOPE THAT IS CLEAR ENOUGH.

Before

She stated 12 months but it's only good practise but not essential. Many AIM companies do placing 1/2 months so it all depends.

Regardless there is plenty of cash available until around 2025 and lots of news is due. Happy days.

Rubbish Porky you have not proven anything just made it up and added the same points again. It proves you're a liar everyone can see it.

Besides focus should be on our pipeline, new flow and low market cap. Plenty on offer buy when others are fearful and fear is a false fear partly created by Porky.

Val likely has cash until 2025. What are you talking about.

Plenty of time and news due but everyone here knows what you are doing so it's a waste of your own time. Nobody listens to you.

Porky all talk about is placings the last two years. You ignore many factual points and ignore all the news/outcomes due and low spending.

Show us where you got this information if you are not a liar.

1) R and D tax refund only 200k

2) Stella stating 2 years cash required.

3) 7 months runaway from start of H2 when the most recent Cenkos report stated 700k plus from end of 2023.

I can go on forever most of your posts are deliberately misleading new investors. All because you lost all your money in DDDD and you wish to inflict your pain on all holders here. Bit sad don't you think.

Yes it is a board for shareholders to discuss. Not for people trying to destroy the company with lies.

I hope I made myself clear. World class preclinical compounds if they get through. We have one already.

Hokkaido:

Dr Suzy Dilly, CEO of ValiRx commented: "The peptide drug candidate under evaluation in this agreement has been developed for a completely novel cancer target. This cutting-edge technology has potential to enable a first in class drug development programme to be launched in these important therapeutic areas."

If it passes: Barcelona

Dr Suzy Dilly, CEO of ValiRx commented: "The lead series of drug candidates under evaluation in this agreement have been developed towards a novel interaction with the KRAS protein important in many cancers of high unmet medical need. KRAS has been a target of interest in oncology for a number of years, and this project has potential to provide a unique method to impact this important pathway."

Https://www.valirx.com/cytolytix-limited

It's novel science from leading universities with a good reputation. If you watch the video for CLX you can see for yourself how good the data is so for sure I would class it as top shelf and world class.

Porky nobody vs Adam. I would rather listen to Adam. Previous post from Adam.

The other point to note, is that they only seem to take on an SPV when the formulation is right and the efficacy/pharmacodynamics look promising.

So, whilst any delays are incredibly frustrating as a SH, if any pass these, then they have much more promise than an otherwise lead-generated test material. It's essentially optimised, and to get to that stage in a large pharma could cost 10-15 Million quid.

VAL are good at cost-cutting in this, and seem to do it on a fairly narrow shoe-string.

So, ultimately, you could argue that CLX might be "valued" at 15-20p as is, all these months in, and that any additional SPV could be 10p each, at signature.

But I don't want to annoy the converse posters, so I'll just say that I *personally* think that 10p significantly undervalues the one SPV we have, without considering anything else like the lab; 301; 3M in the bank; the cost of the VAL "shell"; work undertaken with two more evaluations etc.

But I do strongly disagree with the line "it takes years for commercialisation", as that simply isn't true. There are other AIM Biopharma outfits with milestone deals in place for compounds at an earlier stage than CLX001 currently is, wherein formal drug development work had not yet started at contract stage (just concept).

PatientInvestor I also concur strongly with. I do not want to see a negative impact of 201 on any future good news, nor do I think that it is an appropriate time to dilute for growth. The reason for this is that there is a lot currently in the VAL tank, and this should be maximised throughout 2023 with the tools to hand.

Constant lies by Porky. Valirx does not do clinical trials. CLX is unique and can get a deal easily. Synairgen just had one drug so irrelevant. Complete nonsense.

We should be at least 30/40p. CLX is worth at least 20p and can get a deal at any point soon.

Stella did not state we need two years of cash that is a lie. If it is the truth then post the reference and timing of the video otherwise it proves your entire post is misleading.

Yes they can raise about 5 million next year but the only way they can do that is if VAL hits 20, 25p and above. They will not get the allowance at these prices.

We have all these news due so expecting 30,40p at least this year.

Anyway focus on all the news that is due. They need the votes.

A great time to buy and don't forget all this news due soon:

1) Barcelona update due from Feb which will come

2) Hokkaido update from next week

3) Financials showing significant cash reserves

4) Lab contracts- More than one RNS

5) 201 deal/update

6) 301 update

7) World class new compounds coming through for a quick evaluation in our lab. Each one is worth at least 10p moving into SPV and more overtime so huge potential.

8) CLX- significant updates to come.

Yes I agree. TIme for Suzy to show shareholders if she is a leader or not. Leaders don't sit back. Hokkaido outcome due from this week. Barcelona overdue. Imagine both in one week.

Expecting some significant and game changing news in the next two weeks to allow shareholders to make an informed choice.

Buy low and sell high and a great opportunity for the fearless to buy here.

They have cash until around 2026 subject to warrants being exercised, deal payments, R and D tax credit refund. False and misleading to state R and D tax refunds only just 200k. More likely closer to 1 million.

We should be at least 30/40p. CLX is worth at least 20p and can get a deal at any point soon.

Stella did not state we need two years of cash that is a lie. If it is the truth then post the reference and timing of the video otherwise it proves your entire post is misleading.

Yes they can raise about 5 million next year but the only way they can do that is if VAL hits 20, 25p and above. They will not get the allowance at these prices.

We have all these news due so expecting 30,40p at least this year.

Anyway focus on all the news that is due. They need the votes.

A great time to buy and don't forget all this news due soon:

1) Barcelona update due from Feb which will come

2) Hokkaido update from next week

3) Financials showing significant cash reserves

4) Lab contracts- More than one RNS

5) 201 deal/update

6) 301 update

7) World class new compounds coming through for a quick evaluation in our lab. Each one is worth at least 10p moving into SPV and more overtime so huge potential.

8) CLX- significant updates to come.

We need to make an informed decision regarding the votes for roles. At the moment we only see good progress with CLX despite all the potential with all the other compounds.

RNS can only be released when news is available but that said the outcome of Hokkaido and Barcelona should be announced prior to the AGM otherwise it puts BOD at risk of being booted.

Given updates for 201 and 301 have been handled poorly it is essential that shareholders see progress.

1) No buy and build at these prices. Resolution 4 made it clear shareholders do not support it at these prices.

2) Barcelona update

3) Hokkaido update.

We don't expect everything but we need them to hit at least some targets which at the moment it is not happening.

A £100k buy at 10p gets you £500k at 50p.

I would say 80% chance of that happening in the next 12-18 months.

CLX will almost certainly be worth 30p plus on its own once toxicology studies have been done. Once a deal comes it could be worth 100p as a standalone.

Backed by strong data from Kings College London:

https://www.valirx.com/cytolytix-limited

Two more in the evaluation stage. Each one is worth at least 10p on signature with partnership with these leading universities. More will come in and each will grow in value very fast.

Just like people say buy and build is still on despite a no vote on resolution 4 and shareholder anger we can say the same about 201. Officially 201 is still on unless the company states otherwise. If that gets completed even months later SP can hit 50p alone just on that. See past SP moves for 201.

3 years worth of work has been done on 301. If that was not promising then it would be in the bin. Suzy stated recently she gets more emails about 301 work than anything else so tells us it is on. Once the RNS comes it could be worth 10-20p alone.

Risk to reward is the best in AIM history imo. We need detailed outcomes before the AGM from the BOD to make informed choices.

Two big evaluation updates due this month. Barcelona and Hokkaido. Moving this into SPV will bring deals and speculation.

We need an outcome before AGM to make an informed choice. A complete thorough update expected to win votes.

TIme to buy is now. 9p to 54p is a 500% rise.

ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, has entered into an evaluation agreement with University of Barcelona (Spain) to investigate a drug candidate for use in oncology.

Under the agreement, the Company will carry out a defined series of preclinical tests on a lead series of peptidomimetic drug candidate molecules over the next twelve months to validate the technology and determine suitability for commercialisation. This preclinical evaluation, the cost of which will be borne by ValiRx of up to £100,000, will investigate the mode of action and potential utility as a treatment of KRAS (a GTPase protein made by the oncogene, Kirsten Rat Sarcoma Virus) dependent cancers including Uterine and Pancreatic Cancers.

At the conclusion of the evaluation period (February 2023), the Company has an option to license the technology on pre-agreed terms.

Dr Suzy Dilly, CEO of ValiRx commented: "The lead series of drug candidates under evaluation in this agreement have been developed towards a novel interaction with the KRAS protein important in many cancers of high unmet medical need. KRAS has been a target of interest in oncology for a number of years, and this project has potential to provide a unique method to impact this important pathway."

University of Barcelona research group's Principal Investigator: "KRAS is a known therapeutic target for several cancers, but until recently, it has been undruggable. However, we have found a way to interact with this target. The partnership between University of Barcelona and ValiRx is essential to accelerate the development of those promising results that we have achieved. This agreement will reinforce the project and provide valuable data to progress towards clinical development."

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR"). The Directors of the Company take responsibility for this announcement.

*** ENDS ***